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Abstract
Background: A large and compelling clinical evidence base has shown that integrated TB and HIV services leads to
reduction in human immunodeficiency virus (HIV)- and tuberculosis (TB)-associated mortality and morbidity. Despite
official policies and guidelines recommending TB and HIV care integration, its poor implementation has resulted in
TB and HIV remaining the commonest causes of death in several countries in sub-Saharan Africa, including South
Africa. This study aims to reduce mortality due to TB-HIV co-infection through a quality improvement strategy for
scaling up of TB and HIV treatment integration in rural primary healthcare clinics in South Africa.
Methods: The study is designed as an open-label cluster randomized controlled trial. Sixteen clinic supervisors who
oversee 40 primary health care (PHC) clinics in two rural districts of KwaZulu-Natal, South Africa will be randomized
to either the control group (provision of standard government guidance for TB-HIV integration) or the intervention
group (provision of standard government guidance with active enhancement of TB-HIV care integration through a
quality improvement approach). The primary outcome is all-cause mortality among TB-HIV patients. Secondary
outcomes include time to antiretroviral therapy (ART) initiation among TB-HIV co-infected patients, as well as TB
and HIV treatment outcomes at 12 months. In addition, factors that may affect the intervention, such as conditions
in the clinic and staff availability, will be closely monitored and documented.
Discussion: This study has the potential to address the gap between the establishment of TB-HIV care integration
policies and guidelines and their implementation in the provision of integrated care in PHC clinics. If successful, an
evidence-based intervention comprising change ideas, tools, and approaches for quality improvement could inform
the future rapid scale up, implementation, and sustainability of improved TB-HIV integration across sub-Sahara
Africa and other resource-constrained settings.
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Background
Tuberculosis (TB) is the commonest opportunistic infec-
tion and cause of death among human immunodeficiency
virus (HIV)-infected patients in resource-limited countries
[1]. In 2015, there were an estimated 10.4 million new
(incident) TB cases worldwide, of which 5.9 million (56%)
were among men, 3.5 million (34%) among women, and
1.0 million (10%) among children. In addition, people
living with HIV accounted for 1.2 million (11%) of all the
new TB cases [2]. In 2014, the World Health Organization
(WHO) reported 83% incident TB cases worldwide out of
which one third of these new TB cases originated from
the African continent with high burden countries (HBCs)
[3]. A similar trend was documented in the 2016 WHO
global TB report which showed that the proportion of TB
cases living with HIV was highest in the WHO African
Region (31%) and exceeded 50% in parts of southern
Africa [2].
The extent of the combined TB and HIV epidemics in
South Africa has created enormous operational challenges
for healthcare delivery [4]. Prior to the implementation of
TB-HIV integration, the South African healthcare system
provided separate vertical programmes for TB and HIV
services delivered by different healthcare staff, often
located in separate clinics [4–6]. The vertical model of
delivering TB-HIV care to co-infected patients relied upon
referral and linkage to care programmes (between TB and
HIV programmes and vice versa). This proved problem-
atic and inefficient as referral between programmes
depended chiefly on patients’ resources and health-
seeking behavior which was unmonitored [4, 6].
Integration according to Uyei et al. (2014) is opera-
tionalized by three domains: functional, organizational,
and clinical integration [7]. An integrated model of TB
and HIV healthcare service delivery is an efficient use of
health system’s resources that would address the two
very important co-epidemics [8]. A number of studies
provide evidence of the relationships in the integration
framework that applies to TB and HIV healthcare
delivery [7, 9–11]. However, the optimum model for inte-
grated TB-HIV services in a clinical setting is unknown.
South African guidelines on TB-HIV integration
The South African Department of Health (SA DoH) has
developed guidelines and policies supportive for the in-
tegration of TB-HIV services. The key focus areas for
TB-HIV integration as standard of care in the most re-
cently updated SA DoH guidelines [8, 12–14] is outlined
in Table 1.
Clinical benefit of known TB-HIV integration interventions
Randomized controlled trials have demonstrated that
early initiation of ART during TB therapy improved sur-
vival of TB-HIV co-infected patients by 56% [15, 16].
Additionally, initiating ART early during TB treatment
(within 2–4 weeks) increased AIDS-free survival by 34–68%
among patients with advanced HIV disease [15, 17, 18]. In
spite of TB-HIV integration being incorporated into inter-
national and South African guidelines, mortality rates in
2015 for TB-HIV co-infected patients in South Africa was
133 per 100,000 population, which is more than three
times higher than mortality in HIV-negative TB patients,
who had mortality rates of 46 per 100,000 population [2].
Initiation of cotrimoxazole preventive therapy (CPT)
before or with ART, irrespective of CD4 count, in co-
infected patients has been shown to reduce severe
bacterial infections in an observational study [19] and
mortality by 27% in a multi-site randomized clinical trial
(RCT) conducted in Africa [20]. The clinical benefits as-
sociated with the use of CPT was adopted by WHO for
use as an adjunctive therapy for improved outcomes in
the management of TB and HIV co-infected patients in
the 2014 treatment guidelines [20–22]. In addition, find-
ings from a RCT conducted in South Africa showed that
12 months of isoniazid preventive therapy (IPT) con-
ferred a 37% reduction in risk of active TB in ART-naïve
patients [23]. The benefit of 6 months of IPT and early
ART irrespective of baseline CD4 count was also re-
cently confirmed in the TEMPRANO study that showed
44% lower risk of severe HIV-related illness and a 35%
lower risk of death from any cause [24].
Rationale of the study
Despite the inclusion of the evidence above in standard
TB and HIV treatment guidelines, implementation of
these interventions as part of TB-HIV integration in
South Africa remains poor [23, 25, 26]. Premature mor-
tality from TB and HIV in women and men account for
53.7 and 24.2% of deaths in the 15–24 year age group
and for 44.4 and 47.2% of deaths in the 25–64 age
group, respectively [27]. Cost-effective and sustainable
strategies to strengthen integration of known effective
TB-HIV interventions in primary health care (PHC)
clinics, the main service delivery point for millions of pa-
tients, will abrogate the high mortality associated with
Table 1 Focused areas for TB-HIV integration
▪ Testing and counseling for HIV in all patients with TB.
▪ Intensified case finding for TB in HIV-infected patients.
▪ Isoniazid preventative therapy (IPT) for HIV-positive patients that
screen TB negative.
▪ ART initiation for all TB-HIV co-infected patients.
▪ Cotrimoxazole therapy for TB-HIV co-infected patients.
▪ Enhanced retention in care strategies including the post-test counseling
and use of community-based outreach workers.
▪ Enhanced ART and TB treatment adherence strategies including the
use of community care workers for adherence support and
community-based management of selected patients.
▪ A fully integrated data management system—adopting the
approach of one patient, one appointment, one file, and one data
management system.
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TB-HIV co-infection [28]. A systematic review by Uyei
and colleagues in 2011 of observational studies using
secondary data on TB-HIV integration in sub-Saharan
Africa found several benefits from integration and iden-
tified the need for additional research to identify barriers
to integration as well as strategies to improve TB-HIV
integration [26].
Theoretical framework
Models of TB-HIV integration have ranged from TB
clinics referring patients to HIV clinics and vice versa to
full integration where both services are available at a
single facility, on the same day, by the same healthcare
worker [5]. A group of South African researchers devel-
oped a model to illustrate the critical health system
mechanisms that are essential to operationalize TB and
HIV service integration [7]. Implementing integration re-
quires Functional integration which is the extent to
which integration is supported at the policy and budget
level; Clinical integration which is the extent to which
TB and HIV care, treatment, diagnostic testing, and
health education activities are taking place concurrently;
and Organizational integration which is the extent to
which facility level resources (e.g., staff, infrastructure,
space, patient files, and data systems) and processes
(e.g., patient flow) are integrated [7]. While the model
efficiently explains what is needed to integrate TB and
HIV services, it does not illustrate how TB and HIV ser-
vice integration should be integrated. Quality improve-
ment as a method to improve organizational and clinical
integration is on the cusp of widespread roll out in
South African Department of Health facilities and there
is enough support and political will for creating a culture
of quality improvement (QI) in facilities [8, 14, 29].
We propose a theoretical framework which is an adap-
tation of the Uyei et al. (2014) model that demonstrates
the central role of QI as a catalyst to operationalizing in-
tegration. The SUTHI study intervention has targeted
PHC supervisors and frontline clinic staff as the
recipients of the QI intervention. Figure 1 illustrates that
through continuous QI activities, we theorize that
organizational and clinical integration can be improved
and strengthened and lead to improved patient and
organizational outcomes. Using the collaborative break-
through series approach, developed by the Institute of
Healthcare Improvement (IHI) [30–33], we propose that
a series of timed collaborative learning sessions that
brings intervention clinics together coupled with men-
torship visits at the facility level will impact clinical and
organizational integration activities. Our framework
Fig. 1 SUTHI study theoretical framework. IPT isoniazid preventive therapy, CPT cotrimoxazole preventive therapy, PLWHA people living with
HIV/AIDS, ICF intensified case finding, HCT HIV counseling and testing
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proposes that QI alone may not be sufficient to bring
about improvements in integrated service delivery hence
evaluating, measuring, and monitoring environmental
and contextual factors (confounders) as well as deliver-
ing a good quality QI intervention is key to improving
TB, HIV, and integrated TB-HIV services.
Methods
Aims and objectives
This study aims to reduce mortality due to TB, HIV, and
TB-HIV co-infection through a QI strategy for scaling
up of TB and HIV treatment integration in rural PHC
clinics in South Africa. The hypothesis is that survival
rates will be lower in TB, HIV, and TB-HIV co-infected
patients accessing health care at clinics implementing
the study intervention to deliver integrated TB-HIV care,
compared to survival in patients accessing health care at
clinics that provide only the standard of care for people
with TB and or HIV.
Specific objectives include:
1. To determine the impact of a QI-mediated TB-HIV
care integration on patient mortality.
2. To determine the effectiveness of peer-led QI
approach to enhance integration of TB-HIV
healthcare delivery.
3. To identify clinic-level factors that impact on the
implementation of integrated TB-HIV services.
4. To determine the cost-effectiveness of implementing
TB-HIV integration using the QI approach.
5. To develop an intervention, comprising QI-based
change ideas, tools, and approaches for the scale up,
implementation, and sustainability of integrated
TB-HIV services across South Africa and in other
resource-constrained settings.
Study setting and design
This is an open-label cluster randomized controlled trial
where the cluster is defined as the group of clinic(s)
under the same PHC clinic supervisor, where each of the
16 PHC clinic supervisors may oversee between 3 and 5
PHC clinics. Cluster randomization was chosen for prac-
tical reasons because the study will be carried out in
pragmatic settings involving 40 PHC clinics within the
King Cetshwayo district (formerly called uThungulu) [34]
and Ugu districts in KwaZulu-Natal, South Africa. A total
of 11.1 million people (19.9% of the South African popula-
tion) live in KwaZulu-Natal [35]. The province has the
highest TB-HIV disease burden in South Africa with an
estimated TB-HIV co-infection rate of 70% [12, 36]. The
two districts were selected because they are rural with
high burden of TB, HIV, and TB-HIV co-infection, despite
TB and HIV treatment services in accordance with
current guidelines being available [13, 14, 37]. In 2016,
82.3% of TB-HIV co-infected patients were initiated on
ART in KwaZulu-Natal, slightly lower than the national
ART initiation rate of 84.5% [38]. King Cetshwayo district,
located on the northern coast of KwaZulu-Natal, has a
population of 937,793, with approximately 80% living in
rural settings [39]. Similarly, Ugu district, situated in
southern KwaZulu-Natal has 86% of its population of
750,214 living in rural areas [38, 40]. The in-hospital case
fatality rate due to TB-HIV co-infection in both King
Cetshwayo district (38.4%) and Ugu district (38.8%) re-
mains high despite ART availability [27]. In 2015, over a
quarter of all deaths in KwaZulu-Natal, irrespective of age
or gender, were caused by TB (15.5%) or HIV (12.2%).
PHC clinics offer community level frontline services and
chronic care for all health ailments, including TB and
HIV. Patient level data for these diseases are routinely
captured electronically [41].
Study population
Anonymized clinical and programme outcome data for
all TB, HIV, and TB-HIV co-infected patients accessing
services in the 40 clinics will be included in the study
analysis. According to estimation from the clinic head-
count data, an average of 4500 patients are seen in the
two districts each month. In addition, the healthcare
workers (HCWs) including PHC supervisors will be
interviewed to collect clinic level information after
obtaining informed consent for participation in inter-
views. These interviews will be collated and analyzed to-
gether with patient level data.
Randomization and study groups
Randomization will occur at the level of the PHC super-
visor. This is being done to avoid contamination of inter-
vention effects into control clinics since each supervisor
routinely supports multiple clinics. Each PHC clinic
supervisor will be randomly assigned in a 1:1 ratio to the
intervention or control arm. The study investigators
would provide a list of facilities and supervisors to be ran-
domized using a computer-generated randomization list
generated by study statistician. In South Africa, a PHC
clinic supervisor fulfills a management role at PHC clinics
[42], and are mandated to ensure smooth clinic operations
through oversight of clinic performance against set targets
including patient clinical outcomes and programme per-
formance targets, and oversees the implementation of
clinical guidelines. Each PHC clinic supervisor may over-
see between three and five PHC clinics within one district.
Therefore, through randomization of 14–16 PHC clinic
supervisors working in both the Ugu district and King
Cetshwayo district, 40 clinics (20 in each arm) will be
enrolled into this study as each supervisor oversees on
average three to five medium-sized clinics. Not all clinics
under the purview of the PHC clinic supervisors
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randomized will be enrolled into the study. Clinics
will be excluded if ART services are not offered on
site, services are run by a single nurse, and if they
are mobile clinics or clinics located within hospitals.
All eligible clinics enrolled in the control arm of this
trial will receive the prevailing standard-of-care for
TB-HIV integration (Fig. 2) in accordance with the
DoH guidelines. While the study team will not
interfere with any additional benefit that control
clinics may receive (for example, support from other
NGOs), changes to the background standard of care
will be recorded systematically and accounted for in
the final analysis.
The quality improvement intervention
Quality improvement is described as a set of continuous
actions through coordinated effort of HCW teams aimed
at accelerating improvements to patient care and health
outcomes [43]. This is done through iterative changes
and peer-to-peer learning about successful changes and
has been demonstrated to significantly improve HCW
performance and lead to sustainable delivery of quality
care with improved health outcomes [30, 43, 44]. The
Institute for Healthcare Improvement (IHI) Breakthrough
Series (BTS) is an example of quality improvement
through learning collaborative, demonstrated to success-
fully impact health outcomes in developing-country
Fig. 2 SUTHI study enrolment, randomization, follow-up, and outcome following TB-HIV integration intervention
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settings [30, 45]. The learning collaborative brings together
clinic teams at regular intervals to learn QI methods and
exchange challenges and successes in efforts to implement
the TB-HIV care pathway (learning sessions). Each clinic
will form a QI team that will work with the PHC super-
visor and QI mentors between these learning sessions to
develop local ideas for implementing a specific area of care,
regularly measure performance using agreed-upon indica-
tors, and bring back those results and emerging best prac-
tices to other clinic teams through periodic learning
sessions. We aim to use this structured implementation
approach to improve reliable delivery of published
evidence-based interventions known to decrease morbidity
and mortality in patients with TB and HIV. The main
measure of the collaborative’s success will be measurable
improvement in the magnitude, maintenance, and speed of
specific steps of TB-HIV integration, ascertained through
time-series analyses. These analyses will be collected and
acted upon in real-time and will include process and out-
come indicators. The magnitude of TB-HIV integration
implementation will be measured by the extent to which
interventions provide measurable improvements in PHC
process indicators from baseline (e.g., coverage of HCT
and IPT services among eligible patients, improvements in
quality of services, proportion of HIV-infected patients of-
fered IPT following a negative TB screening). We will also
track the speed at which each of the eight TB-HIV integra-
tion interventions are implemented (e.g., the number of
months taken to reach 90% implementation of individual
integration interventions) and factors affecting speed of
intervention uptake in the clinics.
Systematic testing of change ideas will be evaluated
through a rapid sequence of steps called the Plan-Do-
Study-Act (PDSA) cycle. The PDSA cycle is a sequential
framework for examining problems, deriving solutions,
measuring progress, and embedding changes leading to
positive outcomes [46, 47]. Selected HCWs from the study
intervention clinics will be trained on QI methodology.
This training will enable establishment of QI teams in
intervention clinics to work test and implement change
ideas to advance implementation of the TB-HIV integra-
tion interventions in rapid cycle (Fig. 1) and exchange suc-
cessful ideas for change with other intervention sites
through the learning collaborative. Furthermore, measures
will be taken to prevent inadvertent cross-contamination
of change ideas (e.g., by avoiding any convening of inter-
vention and control clinics or personnel).
Training, coaching, and mentorship for HCWs
implementing QI in clinics randomized to the
intervention arm
The QI approach promotes front-line staff engagement
in the identification of problems affecting performance
and catalyzing rapid cycle testing of possible solutions in
each of the eight identified TB-HIV integration indica-
tors (Table 1). The QI team at each of the intervention
clinics will include the PHC supervisor from the District
Health Management team, the QI clinic champion, the
clinic’s operation manager, selected clinic staff members,
and a QI coach/mentor represented by a member of the
study team. The QI champion, usually a clinic’s most
senior nursing staff, will be trained to lead and support
QI teams in their facilities using QI methods including
the PDSA model, systems thinking, and the use of data
for improvement.
The QI mentor and champion will be capacitated by
the research team to provide peer-leadership and
mentorship for implementation of QI methodology. In
addition, they will also be capacitated to monitor the
weekly performance of their clinics in achieving key suc-
cesses on the indicators being targeted for improvement.
The QI teams will be established through training of se-
lected health workers to become fully fledged QI leaders
and implementers within their facilities. Only HCWs
experienced in both TB-HIV management and imple-
mentation of national TB and HIV guidelines would be
eligible for QI training.
Implementation of the intervention
Three collaborative learning sessions and additional QI
support (mentoring and coaching) visits at specific time
points during the study period (Fig. 1) will be pre-
arranged. Collaborative learning session one will coach
teams in the use of a range of QI methods and tools
(process mapping, fishbone system analysis, PDSA
cycles, use of line graphs, and other data for improve-
ment). Areas requiring improvement will be identified
and prioritized, and aim statements encompassing spe-
cific aims and targets will be developed. Brainstorming
by the QI team and process mapping will be done to de-
fine a strategy to effect positive change (“a change idea”).
The PDSA cycles tracking a set of predefined indicators
will be reviewed bi-weekly by the QI team to test if the
recently adopted change idea resulted in performance
improvement, throughout the study period. This will
enable the generation of new ideas for improvement, it-
erative testing of these ideas, and monitoring of progress
attained through use of run charts and graphs. Learning
session two, scheduled 6 months later will review learn-
ings for all successful change ideas and challenges
against overall clinic performance, with the goal of scal-
ing back on frequency of QI support meetings for clinics
that are undertaking reliable improvement work. Learn-
ing session three, scheduled at month 12, will be focused
on review and scalability of the final successful change
package. It is anticipated that after learning session
three, the clinic’s QI teams would sustain successful
change ideas. Lessons learned will also be shared and
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Table 2 Data collection tools, sources, and outcome measures
Data to be collected Data source Outcomes measure
TB-HIV integration indicators Clinical outcomes
TIER.Net, community care givers, autopsy
reports
- Mortality rates—number of deaths among
TB and HIV patients accessing care in
study clinics from date clinic enrolled to
18 months post enrolment.
TIER.Net - Proportion of patients retained in
care—proportion of HIV-infected patients
enrolled in care at clinics and alive
12 months.
TIER.Net - Viral load testing coverage—proportion of
patients on ART with viral loads test done
among those eligible for viral load test at
requested time points.
TIER.Net - Viral load suppression—proportion of
patients with undetectable viral load tests
among those receiving 12 monthly viral
load test.
TIER.Net and clinic TB registers - TB treatment outcomes at end of study
period—
- Cure rates: proportion of new smear-
positive patients that are smear-negative in
the last month of treatment and on at
least one other occasion at least 30 days
prior.
- Loss to follow-up rates: proportion of new
smear-positive patients that interrupted TB
treatment for 2 consecutive months or
more.
- Treatment failure rates: Proportion of new
smear-positive patients that are smear-
positive at the end of TB treatment period.
- Death rate: proportion of new smear-
positive patients that died during TB
treatment.
- Transfer-out rate: proportion of new
smear-positive pulmonary TB patients
registered that were transferred to another
district and for whom the TB treatment
outcome is unknown.
Process outcome
- HCT Coverage—proportion of patients
with unknown HIV status tested for HIVTIER.Net, DHIS and clinic-based registers
TIER.Net, DHIS and clinic-based registers - Co-infection—proportion of TB patients
co-infected with HIV
TIER.Net, DHIS and clinic-based registers - Time to ART initiation (in days)—time in
days between diagnosis of HIV infection
diagnosis and ART initiation.
TIER.Net, DHIS and clinic-based registers - TB screening coverage among HIV-infected
patients—
a) Proportion of HIV-infected patients
receiving TB screening and
b) Frequency of TB screening during
follow-up
TIER.Net, DHIS and clinic-based registers - IPT initiation—
a) Proportion of HIV-infected TB negative
patients initiated on IPT and
b) Proportion of patients completing IPT
course.
TIER.Net, DHIS and clinic-based registers - CPT uptake among co-infected patients—
proportion of eligible HIV-positive patients
initiated on CPT
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documented across the intervention teams. At the suc-
cessful conclusion of the projects, the intention is to
scale up a reliable “change package” of successful, tested
changes across all clinics in the two districts, if not
across the entire district.
Standard of care in the control clinics: description of TB,
HIV, and integration services
Since the 2009 endorsement of integrated TB-HIV ser-
vices by the South African National AIDS Council
(SANAC) [48], and adoption of TB-HIV service integra-
tion into policy and practice by the National Department
of Health (NDoH) [29], South African guidelines recom-
mend integration of TB and HIV services by a single ser-
vice provider [8, 49].
Data collection
Data on TB-HIV integration indicators will be obtained
from patient files and existing standard customized elec-
tronic data management systems supported by SA DoH
[4, 41]. Routine clinical information is recorded in paper-
based registers and patient clinic folders housed in clinics
and subsequently captured onto the relevant TB or HIV
electronic system supported by SA DoH. Baseline patient
level data will be collected retrospectively for the
12 months prior to study start and will continue prospect-
ively throughout the study period (Tables 2 and 3). In
addition, HCW interviews will be conducted, using case
report forms, at specific time points during study period
from consenting health workers in both the intervention
and control clinics. Table 2 summarizes the data to be
collected, data source, and outcome measures while
Table 3 presents the study’s schedule of activities.
Study outcome measures
The primary outcome of this study will be all-cause
mortality rate among patients newly diagnosed with TB
and/or HIV. Secondary outcomes will include time to
ART initiation, retention in care, IPT and CPT uptake as
per the current SA DoH guidelines, TB cure rates, viral
load testing rates, and viral load suppression rates.
Sample size estimation
We anticipate that about 6000 HIV-positive patients will
be diagnosed with active TB in the study population dur-
ing a 12-month period. This is based on the assumption
that between 100 and 200 new TB-HIV co-infected
patients are seen in each of the 40 clinics per year. This
translates to an average of 350 patients per cluster
(assume unequal cluster sizes). Assuming a case fatality
rate of 15% in the control arm, coefficient of variation
between 0.25 and 0.35, and a type I error rate of 5%, we
will have 80% power to detect a 30% reduction in mor-
tality. The chances of detecting other levels of effective-
ness are shown in Table 4.
Data management
Anonymized TB, HIV, and TB-HIV co-infected patient
data obtained from electronic software systems sup-
ported by the DoH and clinic-based registers will be col-
lated for quality control and for evaluation of impact
made by the intervention in data quality. Also, iDataFax
version 2014.1.1 which is clinical data management
Table 2 Data collection tools, sources, and outcome measures (Continued)
Data to be collected Data source Outcomes measure
TB-HIV service integration in the facility
macro-environment
Survey instrument developed by Uyei et al.
2014 [7]
Measured TB-HIV integration in terms of:
➢ Organization—such as co-location of ser-
vices, combined patient records, informa-
tion management, and joint training
➢ Structure—existent practice of joint
service delivery,
➢ Process—behavior and practice of
delivering services
➢ Culture—work place culture and personal
identification with integrated service
delivery
Clinic profile tool aimed at assessing clinics’
infrastructure, capacity, and systems in place
to implement TB-HIV integration services
A CAPRISA designed tool - Resources inventory and needs for
implementation of TB-HIV integration
services, e.g., available guidelines, proto-
cols, policies, trained staff.
- Existing quality improvement interventions,
processes and measurements
- District level leadership and support
Clinic culture, leadership, resources, etc. The COACH tool designed by Bergstrom
et al. 2015 [56]
- Clinic leadership and support
- Staff knowledge and skills
- Perceptions of work culture at PHC
Staff Work-related Quality of Life WHO Work-related Quality of Life Scale Work-related quality of life for staff at PHC
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software will be used for the design of case reporting
forms for the HCW interviews and its data entry into
the study’s database. Both intervention and control
clinics will have data mentoring by the study data man-
agement team to ensure that quality of data obtained are
improved, standardized, reliable, and valid. The study
database files will be password-protected, and access to
the files will be limited to authorized study staff
members. Quality control measure will be carried out
periodically throughout the study period prior to the
data analysis.
Statistical analysis
The primary outcome of mortality and secondary out-
comes will be analyzed using cluster-summary methods.
The primary outcome will be analyzed among TB-HIV
co-infected patients only while the secondary outcomes
will be analyzed among TB-HIV co-infected, HIV-only,
and TB-only patients. Mortality rate per arm will be cal-
culated as geometric mean of cluster-level summaries
and will be compared using unpaired t test. The same
technique will be applied to secondary outcomes. The t
test applied in cluster-level summaries is one of the ro-
bust methods of analyzing unmatched trials especially
when there are small number of clusters per arm [50].
Since we have 16 clusters and 40 sub-clusters, multi-
level regression will be used as secondary analyses.
Proportional hazard regression with random effects
(frailty models) will be used for analyses of time-to-
event outcomes. Generalized estimating equations and
mixed effects linear models will be used for binary and
quantitative outcomes, respectively. These models will
take the clustering by PHC supervisor and clinic into ac-
count through the random effects. They will also allow
us to adjust for baseline variables, especially those with
imbalance between arms, as this is likely when clusters
are fewer. The HCW interviews will be summarized
using descriptive statistics such as means and fre-
quencies. Adjusted baseline descriptive statistics will be
calculated as the means of the cluster-level summaries
and characteristics of the two arms will be compared
using t test or rank sum tests. Individual-level summar-
ies at baseline will be compared using t test or rank sum
tests and Fisher’s exact test. Data will be analyzed with
SAS version 9.4 (or higher) (SAS Institute INC., Cary
N.C, USA).
Discussion
Findings from this trial are expected to provide informa-
tion on a scalable strategy (a “change package”) to ad-
dress shortcomings in the implementation of integrated
TB-HIV treatment and services. If successful, the strat-
egy could make a contribution to reducing TB-HIV-
associated mortality and morbidity in South Africa and
other regions of the world where co-infection with TB
and HIV is a concern. In 2013, WHO performed a joint
review of HIV, TB, and prevention of mother to child
transmission (PMTCT) programmes in South Africa,
which recommended the need for context-specific
mechanisms for the delivery of integrated TB-HIV
services at PHC and community level, with particular
focus on improving access to TB and HIV services for
children, adolescents, and key populations. Some studies
Table 4 Power to detect different levels of effectiveness
(keeping number of events constant)
Reduction in mortality (%) Power to detect an effect (%)
10 13
20 42
30 80
40 98
Table 3 Study schedule of activities
Study activity Study time points
Baseline (0–1 month) 6–7th month 12–13th month Monthly (1st–18th month)
Retrospective collection of 12 months data on TB-HIV indicators
from TIER.Net*, DHIS** and clinic-based registers
X
***QI Learning Collaborative (Intervention Clinics Only) X X X
Monthly downloads of data on TB-HIV indicators from TIER.Net*,
DHIS** and clinic-based registers
X
Clinic Profile Survey X X X
TB/HIV Service Integration Survey X X X
Work-related Quality of Life Survey X X X
Context Assessment Survey X X X
Quality Improvement Survey (Intervention Clinics Only) X X X
*TIER.Net—Three Inter-Linked Electronic Register for Tuberculosis
**DHIS—District Health Information System
***QI Learning Collaborative—use of PDSA cycles, run charts, process mapping
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undertaken in the South African PHC clinic setting have
shown that the QI strategy can be effective as an inter-
vention for PMTCT care [51–54]. To date, there have
been no studies that have explored the use of the QI
model as an intervention to improve integration of TB
and HIV treatment. An important component of the QI
model is the PDSA cycle, comprising learning cycles to
test and revise theory-based predictions as recommended
by Taylor et al. (2014) in their systematic review on the
application of the PDSA method to improve quality in
healthcare [55]. We anticipate that the findings from this
trial will offer an affordable and sustainable strategy
through use of the QI model to effectively improve the in-
tegration of TB-HIV programmes. The study results will
be communicated to stakeholders through dissemination
meetings, conferences, and publication in peer-reviewed
journals. Recommendations would be made based on the
study findings for appropriate actions to be considered
and taken by the department of health and relevant au-
thorities in areas with high burden of TB and HIV.
Trial status
Data collection is currently on-going.
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